Vir Biotechnology
@Vir_Biotech
Followers
3K
Following
159
Media
393
Statuses
658
We leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.
San Francisco, CA
Joined October 2017
Join us on Sept. 9 for a fireside chat with our Chief Executive Officer Marianne De Backer, MSc, PhD, MBA, at the @MorganStanley 23rd Annual Global Healthcare Conference. Learn more here ➡️
1
0
3
📣 1 in 3 respondents shared that they do not feel informed enough to identify the barriers to #HepatitisDelta testing and treatment – in the U.S. and globally. Thank you to @Hep_Alliance for presenting findings from the Global Hepatitis Delta Survey at our All-Hands meeting.
1
0
3
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
508
942
4K
🏆 We’re proud to share that The Healthcare Technology Report has named our Chief Executive Officer Marianne De Backer, MSc, PhD, MBA, as one of its Top 25 Biotech and Life Sciences Executives of 2025.
0
0
1
#HepatitisDelta is associated with serious complications such as liver cancer. Awareness and diagnosis are key to improving patient care. 🎥 In this third episode of Let’s Ask!, our Chief Medical Officer Mark Eisner highlights barriers of hepatitis delta testing.
1
0
4
📢 #VirBiotechnology News: Today our Chief Executive Officer Marianne D. De Backer, MSc, PhD, MBA, shares our Q2 2025 corporate update and financial results. Learn more about our latest achievements ➡️
0
0
4
Key milestone in ECLIPSE registrational program 🚀 The initiation of ECLIPSE 3 is an important step forward in our determination to set new standards of care for people living with chronic hepatitis delta. Read more here ➡️ #PatientsAreWaiting #HepatitisD
1
0
2
This past Saturday, we came together to raise awareness about #HepatitisDelta, participating in the HERO 5k run/walk at Crissy Field in San Francisco. We’re grateful to everyone who walked or ran side-by-side with us and cheered us on!
1
0
2
Phase 3 ECLIPSE 2 trial in chronic hepatitis delta initiated 🚀 We are excited to continue to evaluate the potential tobevibart and elebsiran as our registrational ECLIPSE program advances. Read more here ➡️ #PatientsAreWaiting #HepatitisD
0
0
1
🎥 In this episode of Let’s Ask!, our Chief Medical Officer Mark Eisner dives into what the Epidermal Growth Factor Receptor (EGFR) is and why it’s considered an attractive target for cancer therapy. Read more about our EGFR focused clinical trial here ➡️
0
0
1
📣 Hepatitis is a major cause of liver cancer and the world’s deadliest virus after COVID-19 – facts that often go unnoticed. On #WorldHepatitisDay, we’re joining @Hep_Alliance in spotlighting hepatitis facts like these to help break down the barriers to a hepatitis-free world.
0
0
3
📣 We are thrilled to see the @Nasdaq MarketSite Tower in the heart of Times Square highlighting us once again, this time for the first patient dosed in the Phase 1 clinical trial of our third dual-masked T-cell engager for the treatment of solid tumors!
0
0
3
📢 First patient dosed in Phase 1 trial of dual-masked #TCE VIR-5525 (CD3xEGFR). We’re excited about the potential of this investigational candidate to improve the lives of people living with cancer. ➡️
0
0
3
👉 #VirBiotechnology will provide a corporate update and report Q2 financial results on Wed., Aug. 6, at 1:30 p.m. PT/4:30 p.m. ET. Join us for our investor conference call. #Earnings
1
0
5
Our CEO, Marianne De Backer, will open the @demy_sara #GlobalBiotechCEOSummit with the Purposeful CEO Series. She’ll share how strategic leadership and a clear mission propelled our expertise in powering the immune system, bringing us to the forefront of masked #TCE technology.
0
1
4
Healthcare providers are a key resource for people with #hepatitisdelta, yet most of the @Hep_Alliance survey respondents did not feel sufficiently informed about testing and treatment. This spotlight's a clear need to strengthen awareness of the disease.
2
0
3
As a panelist for the Student Program session at @IAmBioTech #BIO2025, Jeffrey Herrera, Assoc. Director of Human Resources at #VirBiotechnology, spoke about his own career journey in the biotech industry and how the work can make a lasting difference for patients.
0
0
2
Join a fireside chat with our CEO Marianne D. De Backer, MSc, PhD, MBA, at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 10, at 1 p.m. PT/4 p.m. ET. Watch the webcast live here ➡️ #HepatitisD #Oncology #Immunotherapy
0
0
2
The shared commitment at #ASCO25 to drive better outcomes for people with cancer – moved us. We know there are still many unmet needs of people affected by hard-to-treat solid tumors. #PatientsAreWaiting #Oncology #Immunotherapy
0
0
3
See you at #ASCO25! We look forward to connecting with you about the latest innovations in oncology. We are advancing multiple dual-masked TCEs to develop transformative treatments for people with hard-to-treat solid tumors. Learn more ➡️ #Immunotherapy
0
0
6
As we wrap-up #HepatitisAwarenessMonth, we continue our efforts in increasing awareness of #HepatitisDelta. In this first episode of Let's Ask!, our CMO Mark Eisner, shares key insights about the uniqueness of delta and the need for transformational treatment options.
0
0
4